MetasTx Welcomes Esteemed Cancer Scientist Dr. Jonathan Chernoff to the Board of Managers Dr. Chernoff’s decision to join the Board of Managers reflects his strong belief in MetasTx’s science and strategic direction.

Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.

MetasTx LLC Celebrates Dr. David Crich’s Achievement of the 2024 James Flack Norris Award in Physical Organic Chemistry Dr. David Crich, Georgia Research Alliance, and David Chu, Eminent Scholar In Drug Design and Head of Chemistry at MetasTx honored.

Renown Cancer Expert Joins MetasTx’s Scientific Advisory Board BASKING RIDGE, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- MetasTx LLC, a company driven to create novel therapeutics to treat and prevent metastasis of cancers, today announced that Jonathan Chernoff,...

MetasTx LLC Raises Funds, Engages Manufacturing Partner, And Advances Phase One Development BASKING RIDGE, N.J., June 07, 2022 (GLOBE NEWSWIRE) -- MetasTx LLC is driven to create novel therapeutics to treat and prevent metastasis of cancers. Harvey Homan, CEO and Co-Founder has...